Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetically driven diseases, built around a hub-and-spoke portfolio model. Its lead product, Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, generated
Ex‑U.S., acoramidis is marketed as Beyonttra through Bayer in Europe and Alexion in Japan, contributing license, services, and royalty revenue after 2025 approvals. The company reports multiple late‑stage wins: positive Phase 3 data for infigratinib in achondroplasia, encaleret in autosomal dominant hypocalcemia type 1, and BBP‑418 in LGMD2I/R9, with planned NDA and MAA submissions starting in 2026.
BridgeBio is also advancing encaleret for chronic hypoparathyroidism, infigratinib for hypochondroplasia, and BBP‑812 for Canavan disease, plus an ATTR-CM antibody depleter program. Key risks highlighted include reliance on Attruby/Beyonttra, pricing and reimbursement pressure, clinical and regulatory uncertainty, manufacturing dependence on third parties, and substantial ongoing capital needs.
BridgeBio Pharma reported strong 2025 revenue growth but remains deeply loss-making as it scales commercial and late‑stage programs. Total revenues, net reached $502.1 million for 2025, up from $221.9 million in 2024, driven largely by $362.4 million in Attruby net product revenue and higher royalties from BEYONTTRA.
Operating costs and expenses climbed to $1.03 billion, mainly from a $242.3 million increase in selling, general and administrative spending to support launches, partially offset by lower R&D. Net loss attributable to common stockholders widened to $724.9 million with loss per share of $3.78.
Cash, cash equivalents and marketable securities were $587.5 million at year-end. The company issued $575.0 million of 2031 notes, executed a $300.0 million royalty deal, repaid a $459.0 million term loan and repurchased $48.3 million of stock. BridgeBio highlighted three positive Phase 3 readouts (BBP-418, encaleret, infigratinib) and is planning multiple NDA submissions beginning in the first half of 2026.
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported open-market sales of a total of 28,053 shares of common stock on February 19, 2026. The sales were executed in three tranches of 18,923, 8,528 and 602 shares at weighted average prices of
Following these transactions, Kumar directly owned 234,451 shares of BridgeBio common stock. He also had indirect ownership of 675,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares through the Kumar Haldea Revocable Trust, as co-trustee, while disclaiming beneficial ownership except to the extent of any pecuniary interest.
Reporting persons including Neil Kumar and related trusts reported proposed sales of Common stock under Rule 144. The filing lists multiple
BridgeBio Pharma, Inc. director and CEO Neil Kumar reported equity compensation-related transactions involving restricted stock units (RSUs) and common stock on February 16, 2026. He acquired multiple blocks of common stock at $0.00 per share through the exercise or conversion of RSUs, which each represent a contingent right to receive one share of common stock.
To cover tax obligations triggered by the vesting of 64,698 RSU-based shares, 30,970 shares of common stock were disposed of at $75.25 per share via share withholding, rather than an open-market sale. Following these transactions, he continued to hold a significant number of shares directly, and additional common stock is held indirectly through the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust, where he is a co-trustee. He disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported two transactions in the company’s common stock. On February 17, 2026, Apuli executed an open-market sale of 510 shares at $74.31 per share under a pre-arranged Rule 10b5-1 trading plan. On February 16, 2026, 4,349 shares were withheld to cover taxes tied to the vesting of 8,377 restricted stock units. After these transactions, Apuli directly owned 123,945 shares, which include the 510 shares acquired on February 13, 2026 through the company’s employee stock purchase plan.
BridgeBio Pharma President and CFO Thomas Trimarchi reported a mix of tax withholding and planned share sales. On February 16, 2026, he disposed of 18,819 shares of common stock at $75.25 per share to cover taxes tied to the vesting of 37,503 RSU-based shares. On February 17, 2026, he sold a total of 13,600 shares of common stock in open-market transactions at prices of $74.7068 and $75.38 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 336,585 shares of BridgeBio common stock.
BridgeBio Pharma director Scott Randal W. reported a mix of option exercises and share sales. On February 17, 2026, he exercised stock options for 10,000 shares of Common Stock at $16.75 per share and acquired the underlying shares.
That same day, he sold a total of 10,000 Common Stock shares in open-market transactions at weighted average prices within ranges of $73.74–$76.23 per share, pursuant to a Rule 10b5-1 sales plan adopted on June 27, 2025. After these transactions, he holds 14,896 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
Viking Global Investors and affiliated funds filed Amendment No. 10 to their Schedule 13D on BridgeBio Pharma, Inc. common stock. The reporting group discloses beneficial ownership of 13,026,367 shares, representing 6.8% of BridgeBio’s common stock, with shared voting and dispositive power over all reported shares.
The ownership percentage is calculated from 192,708,813 BridgeBio shares outstanding as of October 21, 2025, less 1,081,825 shares repurchased on January 21, 2026. The amendment updates the identity and structure of the Viking entities and individuals that may be deemed to share authority over this position and notes that recent transactions are listed in an attached exhibit.
BridgeBio Pharma (symbol BBIO) filed a notice of proposed stock sale under Rule 144. The filing covers up to 20,000 shares of common stock, with an aggregate market value of $1,505,000, to be sold through Morgan Stanley Smith Barney on NASDAQ around February 17, 2026.
The shares were acquired the same day through a cash exercise of stock options for 20,000 shares. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.